Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-811P is a pseudogene derived from U6 small nuclear RNA, the most conserved component of the spliceosomal snRNA machinery responsible for intron removal in eukaryotic pre-mRNA splicing[1][3]. While canonical U6 snRNA is essential for spliceosome function, pseudogenes like RNU6-811P are generally non-coding, do not produce functional RNA, and lack established biological function or disease relevance[2]. Many U6-derived pseudogenes exist in the human genome, likely serving as evolutionary remnants, and RNU6-811P is one of these[3]. There is no evidence that RNU6-811P acts as a therapeutic target, nor is there information linking it to drug interaction, mechanism of action, or use as a biomarker. Key points: - RNU6-811P is not a protein, enzyme, receptor, transporter, or active regulatory RNA. - It is one of many U6 snRNA-derived pseudogenes, known as genetic “back-ups” or remnants, and does not have an established role in health or disease[3]. - No indication exists that it is misspelled or an incorrect entity, but as a pseudogene, it is not a druggable or functional target[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 811, pseudogene (RNU6-811P).